Gold is 2025’s best performer. UBS sees more upside
On Friday, Bernstein SocGen Group initiated coverage on Alcon Inc. (NYSE:ALC:SW) (NYSE: ALC) with an Outperform rating and set a price target of CHF97.50. The stock, currently trading at $86.81, appears fairly valued according to InvestingPro analysis, with analysts setting price targets ranging from $80 to $116. Alcon, a leading name in surgical ophthalmology and contact lenses, has been recognized for its substantial investment in research and development, which is considered crucial for market penetration and share.
Alcon’s significant role in the surgical ophthalmology market, valued at $13 billion, and its position as the second-largest player in the $11 billion contact lens market, underpin Bernstein’s positive outlook. With a market capitalization of $43.2 billion and annual revenue of $9.9 billion, Alcon maintains strong financial metrics, including a healthy gross profit margin of 55.7%. The company’s dedication to R&D is highlighted as a strategic advantage, allowing it to introduce innovative products that can potentially expand its market reach.
Since its 2019 spin-off from Novartis (SIX:NOVN), Alcon has accelerated its product introduction pace. The company is preparing to launch seven new products in the United States in 2025. InvestingPro data shows the company maintains a "GREAT" overall financial health score, with strong liquidity ratios and moderate debt levels. For deeper insights into Alcon’s financial position and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro. These products include a new phacoemulsification machine, which is essential for the 30 million cataract surgeries performed annually, and a next-generation PanOptix advanced technology intraocular lens (AT-IOL), designed to minimize the visual disturbances that can deter surgeons from recommending the procedure.
The forthcoming product launches are a testament to Alcon’s commitment to innovation in the field of eye care. The new phacoemulsification machine and the advanced PanOptix AT-IOL are expected to further solidify the company’s market presence and enhance its competitive edge in the industry. With an analyst consensus recommendation of 1.54 (Strong Buy) and projected earnings growth, Alcon appears well-positioned to maintain its market leadership.
In other recent news, Alcon Inc. reported strong fourth-quarter earnings, particularly in its Contact Lens division, which saw an 11% growth rate on a constant currency basis. Following this announcement, Mizuho (NYSE:MFG) Securities raised its price target for Alcon from $110.00 to $115.00, maintaining an Outperform rating. Additionally, Deutsche Bank (ETR:DBKGn) increased its price target to CHF92.00, up from CHF82.00, while keeping a Buy rating, citing Alcon’s optimistic 2025 guidance and strong balance sheet.
Bernstein SocGen Group also reinstated coverage of Alcon with an Outperform rating and a price target of $110.50, highlighting the company’s competitive edge through substantial R&D investments. Meanwhile, Stifel maintained a Buy rating with a $100.00 price target, noting strong interest in Alcon’s newly launched Voyager DSLT glaucoma device, despite some adoption hesitations. Needham adjusted its price target to $106.00 from $108.00, maintaining a Buy rating, due to potential currency impacts on future earnings.
These developments underscore Alcon’s ongoing efforts to expand its market presence through new product launches and strategic investments. Investors are also looking forward to Alcon’s upcoming Capital Markets Day, which may provide further insights into the company’s long-term growth plans.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.